Multiple sclerosis, interferon beta and clinical thyroid dysfunction

Acta Neurologica Scandinavica

Volumn 107, Issue 2, 2003, Pages 154-157

  Kreisler, A ^a   De Seze, J ^a   Stojkovic, T ^a   Delisse, B ^b   Combelles, M ^e   Verier A ^c   Hautecoeur, P ^d   Vermersch, P ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Regional Hospital   (France)

^c Regional Hospital   (France)

^d Centre Hospitalier Saint Philibert GHICL   (France)

^e NONE

Author keywords

Interferon ; Multiple sclerosis; Side effects; Thyroid dysfunction

Indexed keywords

BETA INTERFERON; THYROID HORMONE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERTHYROIDISM; INFORMATION PROCESSING; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE SCLEROSIS; REMISSION; SKIN NECROSIS; THROMBOCYTOPENIA; THYROID DISEASE;

ADULT; ANTITHYROID AGENTS; FEMALE; GOITER; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; THYROID DISEASES; THYROXINE;

EID: 0037291646     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2003.02009.x     Document Type: Article

References (22)

1. GAINES AR, VARRICHIO F. Interferon beta-1b injection site reactions and necrosis. Multiple Sclerosis 1998; 4:70-3.
2. IFNβ MULTIPLE SCLEROSIS STUDY GROUP. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-61.
3. NEILLEY LK, GOODKIN DS, GOODKIN DE, HAUSER SL. Side-effect profile of interferon beta-1b in MS. Neurology 1996; 46:552-4.
4. IFNβ MULTIPLE SCLEROSIS STUDY GROUP. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45:1277-85.
5. MOHR DC, LIKOSKY W, DWYER P, VAN DER WENDE J, BOUDEWYN AC, GOODKIN DE. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis. Arch Neurol 1999; 56:1263-5.
6. SCHWID SR, GOODMAN AD, MATTSON DH. Autoimmune hyperthyroidism in patient with MS treated with interferon beta-1b. Arch Neurol 1997; 54:1169-90.
7. PICHERT G, JOST LM, ZOBELI L, ODERMATT B, PEDIA G, STAHEL RA. Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. Br J Cancer 1990; 62:100-4.
8. BERRIS B, FEINMAN SV. Thyroid dysfunction and liver injury following alpha-interferon treatment for chronic viral hepatitis. Dig Dis Sci 1991; 36:1657-60.
9. LISKER-MELMAN M, DI BISCEGLIE AM, USALA SJ, WEINTRAUB B, MURRAY LM, HOOFNAGLE JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon-beta. Gastroenterology 1992; 102:2155-60.
10. ROTONDI M, OLIVIERO A, PROfICE P et al. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J Endocrinol Invest 1998; 21:748-52.
11. DURELLI L, FERRERO B, OGGERO A et al. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci 1999; 162:74-83.
12. MONZANI F, CARACCIO N, CASOLARO A et al. Long-term interferon beta-1b therapy for MS: is routine thyroid assessment always useful? Neurology 2000; 55:549-52.
13. ROTONDI M, MAZZIOTTI G, BLONDI B et al. Long-term treatment with interferon-beta therapy for multiple sclerosis and occurrence of Grave's disease. J Endocrinol Invest 2000; 23:321-4.
14. MC DONALD ND, PENDER MP. Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis. Aust NZ Med 2000; 30:278-9.
15. KREISS Y, COHEN O, PRAS E, ACHIRON A. Subacute thyroiditis in a patient with MS treated with interferon beta-1A. Neurology 1999; 53:1606.
16. DURELLI L, FERRERO B, OGGERO A et al. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Neurology 2001; 57:1363-70.
17. LO R, FEASBY TE. Multiple sclerosis and autoimmune diseases. Neurology 1983; 33:97-8.
18. ANNUNZIATA P, LORE' F, VENTURINI E et al. Early synthesis and correlation of serum anti-thyroid antibodies with clinical parameters in multiple sclerosis. J Neurol Sci 1999; 168:32-6.
19. WEI T, LIGHTMAN S. The neuroendocrine axis in patients with multiple sclerosis. Brain 1997; 120:1097-76.
20. KARNI A, ABRAMSKY O. Association of MS with thyroid disorders. Neurology 1999; 53:883-5.
21. MARTINELLI V, GIRONI M, RODEGHER M, MARTINO G, COMI G. Occurrence of thyroid immunity in relapsing-remitting multiple sclerosis patients undergoing interferon-beta treatment. Ital J Neurol Sci 1998; 19:65-7.
22. BAUDIN E, MARCELLIN P, POUTEAU M et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol 1993; 39:657-61.